Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection-Authors' reply
- PMID: 33205870
- DOI: 10.1111/apt.16138
Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection-Authors' reply
Comment on
-
East Asia expert opinion on treatment initiation for chronic hepatitis B.Aliment Pharmacol Ther. 2020 Nov;52(10):1540-1550. doi: 10.1111/apt.16097. Epub 2020 Sep 20. Aliment Pharmacol Ther. 2020. PMID: 32951256 Review.
-
Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection.Aliment Pharmacol Ther. 2020 Dec;52(11-12):1762-1763. doi: 10.1111/apt.16124. Aliment Pharmacol Ther. 2020. PMID: 33205878 No abstract available.
References
REFERENCES
-
- Li ZC, Li Z, Li C, et al. Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection. Aliment Pharmacol Ther. 2020;52:1762-1763.
-
- Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540-1550.
-
- Wong V-S, Adams LA, de Lédinghen V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461-478.
-
- Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773-780.
-
- Wu J-C, Huang Y-H, Chau G-Y, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890-897.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical